Product image of Icatibant Ratiopharm (Icatibant Acetate) supplied by GNH India

Icatibant Ratiopharm

Active Ingredient:
Icatibant Acetate
Origin:
EU

Icatibant Ratiopharm (Icatibant Acetate)

Icatibant acetate, the active ingredient in Icatibant Ratiopharm, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema type I and II in patients with confirmed HAE.
GNH India supplies Icatibant Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Teva B.V

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant Ratiopharm acts on the bradykinin pathway to relieve hereditary angioedema attacks.

  • Hereditary angioedema type I: rapidly reduces swelling during acute episodes.
  • Hereditary angioedema type II: alleviates symptoms of sudden edema.
  • Bradykinin‑mediated angioedema: blocks bradykinin‑driven vascular leakage, improving airway patency.

How It Works

  • Icatibant acetate competitively binds to the bradykinin B2 receptor on endothelial cells, preventing bradykinin from activating the receptor. This inhibition blocks the downstream signaling that normally causes vasodilation, increased vascular permeability, and the resultant swelling characteristic of hereditary angioedema attacks.

Side Effects

Icatibant Ratiopharm may cause a range of adverse reactions following subcutaneous injection.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Injection site erythema: redness around the injection area.
  • Injection site swelling: localized edema.
  • Headache: transient headache episodes.
  • Nausea: occasional feeling of nausea.
  • Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Angioedema at injection site: extensive swelling that may compromise local tissue.
  • Severe hypotension: marked drop in blood pressure.
  • Thrombocytopenia: low platelet count observed in rare cases.
  • Severe injection site necrosis: tissue death at the injection site.

Precautions & Warnings

Before using Icatibant Ratiopharm, consider the following safety measures.

  • Hypersensitivity assessment: avoid use in patients with known allergy to icatibant or formulation components.
  • Airway monitoring: observe for signs of airway obstruction during acute attacks.
  • Concomitant bradykinin antagonists: do not combine with other B2 receptor blockers.
  • Renal or hepatic impairment: use with caution; adjust monitoring as clinically indicated.
  • Pregnancy and lactation: safety not established; weigh benefits against potential risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant Ratiopharm has limited drug‑drug interactions, but certain combinations require attention.

Major Interactions (Avoid)

  • Other bradykinin B2 receptor antagonists: concurrent use may lead to excessive blockade.
  • ACE inhibitors: may increase bradykinin levels and alter therapeutic response.

Moderate Interactions (Monitor Closely)

  • Angiotensin receptor blockers (ARBs): monitor for additive effects on blood pressure.
  • Diuretics: observe for changes in fluid balance.
  • Immunosuppressants: watch for altered immune response at injection site.

Frequently Asked Questions

Icatibant Ratiopharm is used to treat acute attacks of hereditary angioedema type I and type II. It works by rapidly reducing swelling and relieving symptoms during sudden HAE episodes.

Icatibant acetate blocks the bradykinin B2 receptor, preventing bradykinin from causing vasodilation and increased vascular permeability. This inhibition stops the swelling cascade that characterises hereditary angioedema attacks.

The prescribed dose is determined by the treating physician based on the patient’s condition and clinical guidelines. Dosing instructions are individualized and should be followed exactly as directed by a healthcare professional.

Safety data for icatibant in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified clinician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Icatibant is a selective bradykinin B2 receptor antagonist, whereas other options such as C1‑esterase inhibitor concentrates replace a deficient protein. Icatibant offers rapid subcutaneous administration and targets the downstream mediator directly, providing an alternative mechanism of action.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Follow the manufacturer’s packaging instructions to maintain product stability.

Icatibant Ratiopharm is supplied as a sterile injection solution for subcutaneous use. The dose is injected into the subcutaneous tissue, typically in the abdomen or thigh, by a trained healthcare professional or as instructed by the prescriber.

Serious risks include anaphylactic reactions, severe hypotension, extensive angioedema at the injection site, and rare cases of thrombocytopenia. Patients should be monitored closely for any signs of these events and seek immediate medical attention if they occur.

Patients with known hypersensitivity to icatibant acetate or any component of the formulation should avoid its use. Additionally, individuals receiving other bradykinin B2 antagonists or with uncontrolled severe cardiovascular conditions should be evaluated carefully before treatment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant Acetate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT